SCHEMBL13289563

SCHEMBL13289563

Bc1cnn2c(NCc3cccc(NC(=O)Nc4cccc(C)c4)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 6/20 0.50
▸ GSK3B P49841 5/20 0.50
▸ CYP1A2 P05177 4/20 0.46
▸ CYP3A4 P08684 4/20 0.46
▸ CYP2C19 P33261 4/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ HCRTR1 O43613 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ KCNN3 Q9UGI6 1/20 0.42
▸ CYP2D6 P10635 3/20 0.42
▸ TSHR P16473 2/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ PTGER3 P43115 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ EPHB4 P54760 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289245 0.94 CDK2 (0.49) CDK2GSK3BCYP1A2CYP3A4CYP2C19
SCHEMBL13289700 0.92 CDK2 (0.47) CDK2GSK3BCYP1A2CYP3A4CYP2C19
SCHEMBL13289334 0.92 CDK2 (0.49) CDK2GSK3BCYP1A2CYP3A4CYP2C19
SCHEMBL13121740 0.91 CDK2 (0.63) CDK2GSK3BCYP1A2CYP3A4CYP2C19
SCHEMBL14301776 0.91 CDK2 (0.51) CDK2GSK3BKDREPHB4AURKA
SCHEMBL12954468 0.91 CDK2 (0.51) CDK2GSK3BMEN1KMT2AEPHB4
SCHEMBL13289340 0.90 CDK2 (0.48) CDK2GSK3BPTGER3KDR
SCHEMBL13289304 0.90 CDK2 (0.48) CDK2GSK3BMEN1KMT2AALDH1A1
SCHEMBL12954205 0.89 CDK2 (0.49) CDK2GSK3BPTGER3KDREPHB4
SCHEMBL13289540 0.89 CDK2 (0.49) CDK2GSK3BCYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback